These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39226127)

  • 1. Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer.
    Fan C; Lou S; Shen C; Liao J; Ni H; Chen S; Zhu Z; Hu X; Xie W; Zhao H; Cui S
    J Med Chem; 2024 Sep; 67(17):15291-15310. PubMed ID: 39226127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
    Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
    Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
    Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
    Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3.
    Fan D; Liu P; Li Z; He X; Zhang L; Jiang W; Ang W; Yang T
    Bioorg Chem; 2024 Sep; 150():107565. PubMed ID: 38905884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
    Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
    Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
    Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
    Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H; Clamor C; Müller K
    J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.
    Huang R; Jing X; Huang X; Pan Y; Fang Y; Liang G; Liao Z; Wang H; Chen Z; Zhang Y
    J Med Chem; 2020 Feb; 63(4):1544-1563. PubMed ID: 31999451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
    Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
    Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
    Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
    Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
    Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
    Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
    Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Optimization of Marine Natural Product Pretrichodermamide B for the Treatment of Colon Cancer by Targeting the JAK/STAT3 Signaling Pathway.
    Zhou Y; He N; Liu Q; Li R; Yang L; Kang W; Zhang X; Xu X; Yao G; Wang P; Wang CY; Yang J; Liu Z
    J Med Chem; 2024 Jul; 67(13):10783-10794. PubMed ID: 38888591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
    Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
    Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
    Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
    Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.